Sentences with phrase «smaller phase i trial»

In a few weeks, meeting participants learned, enough data may be available from small phase I trials of a vaccine jointly made by the U.S. National Institute of Allergy and Infectious Diseases and GlaxoSmithKline (GSK) that began in September to launch efficacy studies.

Not exact matches

The results, which mirror those of similar, small - scale studies of the illegal drug in recent years, come as MDMA is about to enter larger, Phase 3 trials this summer.

A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (SCLC).

Success with these models led to a small phase I clinical trial in which an individual's good bacteria with antimicrobial activity was grown, formulated in a skin cream and applied once to the forearm of the eczema patient infected by S. aureus.

The HYPO - RT - PC trial, a randomized multi-institutional phase III trial in Scandinavia, was designed to assess outcomes from highly accelerated extreme hypofractionation, which is delivered in smaller number of high doses — seven fractions of 6.1 Gy each in this study.

This phase III trial followed earlier evidence suggesting that small doses of aspirin and clonidine can ward off heart attacks and heart - related death for such patients.

In 2011, Science's editors will be watching a smaller detector at the Large Hadron Collider called LHCb, which will study B mesons in great detail; new techniques that should lead to the discovery of many more genes contributing to adaptation; an ignited fusion burn at the National Ignition Facility; broadly neutralizing antibodies, which are capable of disabling a wide range of viral variants; the first plug - in hybrid electric cars whose batteries are charged from a wall socket go on the market; and the results of the first phase III trial of a malaria vaccine.

In phase I trials, researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

For the investigators involved in the research, the results, though obtained in a relatively small, phase 1 trial, are compelling.

Her research at Stanford University has contributed to the development of a small molecule peptide that is currently in Phase IIA clinical trials for AD.

The small, phase 1 trial enrolled 11 patients and found that side - effects were similar in this population as previously reported in larger trials of enzalutamide against prostate cancer.

«The immune responses are there, the tough call is whether they're enough to protect humans against Ebola, and I guess we'll find that out in the phase 3 trial,» says Adrian Hill, director of the Jenner Institute in Oxford, UK, who is leading a small safety trial of the monovalent NIAID / GSK vaccine.

In a small phase I and II clinical trial, Johns Hopkins researchers and colleagues elsewhere found that the high - fat, low - carbohydrate ketogenic diet was a safe and effective treatment option for the majority of adults experiencing a relatively rare, often fatal and always severe form of epilepsy marked by prolonged seizures that require medically induced comas to prevent them from further damaging the body and the brain.

In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI - 110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer.

In September, Alnylam Pharmaceuticals announced that its small RNA molecules silenced the gene that causes the progressive disease hereditary ATTR amyloidosis in a successful phase III trial.

Dr. Henry noted that while ATHENA observed a small patient population, the results are promising and consistent with what was seen with PRECISE and should provide the foundation for a large phase 3 trial.

Women age 25 - 65 who have been diagnosed with HPV 16 or HPV 18 are needed to participate in a small Phase I tolerability clinical trial of GTL001 with only a three - month follow - up period.

Adding the monoclonal antibody drug trastuzumab — already used to treat certain breast cancers — to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value.

Phase I trials are generally small (less than 100 participants) and designed to see if the product is safe.

The companies have launched a phase II trial of the antibody - drug conjugate, and are also testing it in other solid tumors, including ovarian and non — small - cell lung cancers.

A randomized, phase II trial showed improved progression - free survival in small - cell lung cancer with maintenance sunitinib vs placebo following standard chemotherapy, according to results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

He concluded that the improvement in progression - free survival and potential for overall survival benefit should lead to a phase III trial of this therapy option in small - cell lung cancer.

Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions

A small, phase 1 trial, published early online in the journal Radiology, found that this approach, designed to treat just the diseased portion of the prostate rather than removing or irradiating the entire gland, is safe and can be performed without the troubling complications associated with more aggressive therapies.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma

Texas Children's Cancer Center is a member of the COG Phase I Consortium, a small and select group of institutions that administer Phase I clinical trials of drugs in early development.

The Animal and Human Imaging Shared Resource enables Cancer Center investigators to execute high throughput, quantitative and noninvasive in vivo imaging studies on animal models, apply and validate MRI, optical, CT, PET, SPECT and ultrasound methods for noninvasive detection and characterization in small animals and incorporate emerging and clinical relevant quantitative MRI and PET protocols into Phase I, II and III clinical trials in a centralized, cost effective manner.

Omecamtiv mecarbil is a selective, small - molecule currently being studied in a Phase 3 clinical trial of ~ 8000 patients as a potential treatment for heart failure with reduced ejection fraction in collaboration with Amgen and in partnership with Servier.

Phase 2b trials are larger than phase 2 (sometimes involving thousands of participants), but smaller than a phase 3 sPhase 2b trials are larger than phase 2 (sometimes involving thousands of participants), but smaller than a phase 3 sphase 2 (sometimes involving thousands of participants), but smaller than a phase 3 sphase 3 study.

«After his experiments demonstrated improvements in memory and «rejuvenation» in the brain in old mice with young blood, we thought to try a small, phase one trial, in patients.»

With carefully designed Phase I clinical trials, they begin with small, effective doses and gradually increase to determine the correct dosage and to observe the toxicity of new therapies.

Establishment of a collaboration with the European Lung Cancer Working Party which led to a phase II study on patients with refractory or relapsing small cell lung cancer (clinical trial # 1081 - http://www.elcwp.org/).

Phase 1 trials would be small, nongenerablizable empirical studies whose dependent variable is not year - end test scores, but «next - day or next - week outcomes: measurable effects on student behavior, effort, or short - term learning.»

Phase 1 trials would be small, nongeneralizable empirical studies of teacher moves.

Only a relatively small number of personal injury cases will proceed to the trial phase.